Wolwo Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 318 million yuan, an increase of 2.46%
I'm LongbridgeAI, I can summarize articles.Wolwo Pharma released its 2024 annual report, with operating revenue of 925 million yuan, a year-on-year increase of 9.10%; net profit attributable to the parent company of 318 million yuan, a year-on-year increase of 2.46%; and net profit excluding non-recurring gains and losses of 306 million yuan, a year-on-year increase of 2.72%. The basic earnings per share are 0.607 yuan, and it plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders
According to the Zhitong Finance APP, Wolwo Pharma (300357.SZ) released its annual report for 2024, reporting an operating income of 925 million yuan, a year-on-year increase of 9.10%. The net profit attributable to shareholders of the listed company was 318 million yuan, a year-on-year increase of 2.46%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 306 million yuan, a year-on-year increase of 2.72%. The basic earnings per share were 0.607 yuan. In addition, it plans to distribute a cash dividend of 1.20 yuan (including tax) for every 10 shares to all shareholders